drugset / Trial / NCT03136237

A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions

NCT03136237

Phase 1 Completed 54 enrolled BioCryst Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, three part study to evaluate the effect of BCX7353 on drug transporters as well as the effect of an inhibitor of drug transport on BCX7353.

Timeline

Start
2017-02-17
Primary completion
2017-08-15
Completion
2017-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 600 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral
Subject berotralstat Small molecule 350 mg Oral

Indications